Aerosol Products

Oral Spray Device Testing

Particle size, spray pattern, emitted dose, and use-condition testing for oral spray devices.

Controlled actuation, oral-interface fixtures, particle sizing, plume imaging, dose collection, and assay support for development and regulatory documentation.

ISO 17025USP <601> (inhalation/nasal only)ISO 13320FDA nasal / inhalation sprayReviewed 2026-10-06
Request a quoteSubmit a sample

Testing oral spray devices

Oral spray testing connects the pump, actuator, nozzle, formulation, dose volume, and user interface to measured output. Mouth and throat sprays use product-specific protocols for droplet size, geometry, emitted dose, and collection. USP <601> and FDA nasal or inhalation guidance apply only when the product falls within those delivery scopes. Testing supports decisions when:

  1. PSD testing compares oral spray formulations, pumps, and nozzles using ISO 13320 laser diffraction or aerodynamic sizing when respirable aerosol is a concern.
  2. Spray pattern and plume geometry compare actuator, nozzle, or viscosity changes under a defined protocol; ISO 17025 quality records document imaging and actuation conditions.
  3. Dose studies quantify actuation-to-actuation output, priming state, and orientation effects under a product-specific protocol, with collection and assay controls documented in ISO 17025 quality records.
  4. Breathing simulation evaluates mouthpiece geometry, inhalation timing, and oral fixture collection using product-specific profiles, with use assumptions and controls documented in ISO 17025 quality records.
  5. Product-specific storage pulls track PSD, plume, emitted dose, clogging, and residue; ICH Q1A applies only to drug products within its scope.

Use oral spray testing when droplet size, plume direction, dose consistency, or user coordination could change delivered material. Before samples arrive, the protocol defines the actuation sequence, oral-interface geometry, collection endpoint, assay plan, and how results will be judged against acceptance criteria.

Core test menu for oral spray devices

Oral spray programs usually combine particle sizing, plume imaging, dose collection, and breathing simulation. The choice depends on device geometry, formulation state, comparator strategy, and the documentation needed.

Test method options

MethodStrengthsTradeoffAligned with
Oral spray PSD and droplet-size screen
  • Laser diffraction under ISO 13320 compares formulations, pumps, nozzles, and spray counts; aerodynamic measurements use a separately defined sizing protocol.
  • Rapid screens identify respirable fractions, droplet drift, and formulation effects before committing to larger dose or fixture studies.
Optical or aerodynamic size data do not prove delivered active mass; pair with emitted-dose recovery when dose is the decision.
ISO 13320
Spray pattern, plume geometry, and high-speed imaging
  • Laser sheet and high-speed imaging quantify plume angle, width, footprint, breakup, and pulsing under a defined oral-spray imaging protocol.
  • Controlled distance, orientation, and trigger timing isolate nozzle or formulation effects from operator technique.
Imaging endpoints describe spray behavior, not recovered material; combine with PSD or dose data for delivery claims.
Emitted dose and dose-uniformity series
  • Defined actuation sequences measure emitted dose, priming effects, orientation, and spray-count variability with product-specific collection and assay controls.
  • Assay recovery controls connect collected material to active, tracer, or surrogate concentration for traceable product documentation.
Collection adapters and assay readiness drive setup time when device geometry or formulation matrix is new.
Breathing and oral-interface simulation
  • Programmable breathing profiles test mouthpiece geometry, inhalation timing, and collection efficiency using documented oral-spray profiles and collection controls.
  • Oral fixtures and mannequins support exposure, deposition, and use-condition comparisons without claiming clinical replacement.
Results depend on profile assumptions and fixture geometry; those assumptions must be declared before interpretation.
Stability-linked spray performance pulls
  • Conditioned pulls track PSD, plume, emitted dose, residue, and clogging under product-specific storage conditions; ICH Q1A is reserved for applicable drug products.
  • Trend plots connect formulation or package changes to measurable output shifts before shelf-life or comparator decisions.
Study duration follows storage and pull timing; analytical scheduling should be planned before conditioning begins.
ICH Q1A (drug products only)

Setup configurations

Device geometry, actuation behavior, formulation state, and the endpoint determine how we set up an oral spray study. The same product may need different fixtures for PSD, plume imaging, dose recovery, or breathing simulation. Before testing starts, we define the spray count, priming state, orientation, distance, collection media, environmental conditions, and replicate structure.

Device interfaces

Actuator holders, mouthpiece adapters, oral-cavity fixtures, collection targets, filters, impingers, and custom holders matched to pump, bottle, or nozzle geometry.

Flow & actuation profiles

Manual, semi-automated, or automated actuation with force, stroke, timing, spray distance, device orientation, breath profile, and shot interval documented per run.

Sample numbers

Device count, spray count, priming state, beginning or end-of-use pulls, and analytical replicates sized to variability, assay sensitivity, and decision risk.

Media & handling

Filters, fixtures, extraction solvents, collection surfaces, storage conditions, cleaning steps, and chain of custody set for active, tracer, or surrogate recovery.

Environmental controls

Temperature, RH, fill level, conditioning history, residue state, and aging condition logged when formulation viscosity or actuator behavior may shift.

Quality frame for oral spray testing

Oral spray studies run within a documented quality system anchored to accreditation and method references. These references are used most often for aerosol performance, particle sizing, and spray documentation.

  • ISO 17025AccreditedLaboratory competence, calibration traceability, method control, and uncertainty contributors.
  • USP <601> (inhalation/nasal only)AlignedInhalation or nasal drug-product reference only; generic mouth and throat sprays use a separate protocol.
  • ISO 13320AlignedLaser diffraction particle-size analysis for droplet-spectrum studies.
  • FDA nasal / inhalation sprayAlignedNasal or inhalation drug-product guidance only; scope is confirmed before it informs a study.

Key data outputs & reporting

Study datasets connect the device setup to measured spray performance: PSD curves, plume images, emitted-dose statistics, recovery data, breathing-profile collection results, and QA/QC controls. We format reports for development review, troubleshooting, comparability, or interpretation of stability trends. When a program includes storage pulls, comparator devices, or use-condition simulations, extended deliverables include the appendices needed to document that work.

Primary outputs

  • Particle or droplet-size distribution tables, Dv10 / Dv50 / Dv90, aerodynamic fractions, and concentration trends by device condition.
  • Spray pattern area, plume angle, plume width, high-speed image observations, and actuator-to-actuator comparisons.
  • Emitted dose, dose uniformity, active or tracer recovery, deposition mass, and collection efficiency by spray count or fixture location.
  • Breathing-profile and oral-interface notes, including fixture geometry, profile assumptions, sampling locations, and interpretation limits.

Deliverables

#FormatContents
01PDF reportProtocol summary, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsPSD tables, dose statistics, plume metrics, and recovery data.
03Images / videoSpray pattern files, plume frames, overlays, and high-speed video exports.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side PSD, plume, and emitted-dose summaries for reference products or device-change review.
  • Stability trend pack — Timepoint tables and figures showing particle size, plume, dose, residue, and clogging changes.
  • Use-condition notes — Breathing profile assumptions, fixture rationale, collection efficiency notes, and exposure interpretation limits.

QA / QC & data integrity

Each oral spray study has a QA/QC plan matched to the selected endpoints, assay, and documentation needs. Controls run alongside collection, keeping particle, plume, dose, and recovery data traceable from sample receipt through the final report. The study records also document method deviations, invalid runs, and contributors to uncertainty.

Blanks, device-off backgrounds, comparator devices, reference aerosols, or replicate actuations defined by endpoint and collection train.

Flow meters, balances, impactor stages, imaging scales, timers, actuation fixtures, and environmental sensors checked or calibrated before use.

Assay controls for HPLC, GC/MS, FTIR, ELISA, or ddPCR, including calibration standards and recovery checks when required.

Chain of custody for devices, collected filters, fixtures, extracts, image files, instrument exports, and analyst observations.

Predefined acceptance criteria, replicate rules, carryover checks, deviation handling, and outlier logic included in the protocol.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

These answers cover questions oral spray development and regulatory teams ask when planning a study: which endpoints to combine, how devices and actuations are counted, when breathing simulation matters, and what documentation is delivered. Most oral spray programs need at least one product-specific decision about a fixture, actuation, or assay. Those decisions are best resolved during study planning.

Q.Which oral spray test should I start with?
A.Start with the decision the data need to support. PSD describes droplet-size behavior, while plume imaging examines nozzle and spray formation. Dose testing measures output consistency. Breathing simulation evaluates use-condition collection, and many programs combine two or more endpoints.
Q.Can ARE Labs test dose consistency?
A.Yes. Emitted-dose and dose-uniformity studies can be configured around defined actuation force, spray count, orientation, priming state, collection media, and analytical endpoint. The study does not replace clinical dosing or approval work.
Q.How many devices or sprays are needed?
A.Device count, spray count, and replicate count depend on the number of configurations, priming states, endpoints, assay sensitivity, and whether the work is exploratory or documentation-focused. We define counts during protocol development.
Q.When is breathing simulation useful?
A.Use breathing simulation when mouthpiece geometry, inhalation timing, breath-hold assumptions, or oral-cavity collection could change recovered material. The protocol specifies the profile and fixture assumptions before testing.
Q.What data will I receive?
A.Deliverables can include PSD curves, plume images, spray pattern metrics, high-speed video, emitted-dose tables, recovery data, raw files, deviations, QA/QC records, and a written report.
Q.Does this cover full regulatory approval?
A.No. Testing can support product development, method justification, comparator studies, troubleshooting, and regulatory documentation. Clinical studies, labeling review, toxicology programs, and full submission management are outside this page's scope.

Standards & guidance

ARE Labs aligns oral spray programs with the compendial, consensus, and regulatory references that fit the product question. Some oral spray products have no single governing performance standard. The study plan states which references apply, which controls are adapted, and where the protocol is fit for purpose. Accredited scopes are reported as accredited; other references are followed as aligned where applicable.

Inhalation & Drug Delivery - Aligned

USP <601> (inhalation/nasal only)

Inhalation and nasal drug-product performance tests; not a default oral-cavity or throat-spray methodView standard ->Aerosol & Particle Measurement - Aligned

ISO 13320

Laser diffraction particle-size analysis for spray droplet distributionsView standard ->QA & Regulatory - Aligned

FDA nasal / inhalation spray

Nasal or inhalation drug-product guidance; ordinary mouth and throat spray protocols are scoped separatelyView standard ->Inhalation & Drug Delivery - Aligned

ISO 20072

Design-verification context for eligible respiratory-tract aerosol medication devices; not general spray product quality assessmentView standard ->QA & Regulatory - Aligned

ICH Q1A (drug products only)

Drug-product stability guidance within its scope; other oral sprays use product-specific storage protocolsView standard ->

Related testing services

Test

Particle Size Distribution (PSD) Testing

Pairs with oral spray development to compare droplet spectra, respirable fractions, and particle-size drift across formulations, pumps, or storage pulls.Read more ->Test

Spray Pattern & Plume Geometry

Documents nozzle and formulation effects on plume angle, spray width, footprint, and transient spray behavior for comparator or troubleshooting studies.Read more ->Test

Dose Uniformity & Emitted Dose

Measures actuation-to-actuation output, priming state, orientation effects, and recovered active or tracer for metered oral spray devices.Read more ->Test

Breathing Simulation Testing

Adds inhalation profiles, oral fixtures, mouthpiece adapters, and use-condition collection when timing or geometry changes delivered material.Read more ->